SECOND-QUARTER 2020 FINANCIAL RESULTS

LivaNova
Health innovation that matters

Financial Summary [1]

$182M	61%	(2)%	$0.15
Net Sales	Adjusted Gross Margin	Adjusted Operating Margin	Adjusted Loss Per Diluted Share

Sales Summary [2]



- Neuromodulation
- Cardiovascular



US	$78M	⬇ 42%
EU	$35M	⬇ 38%
ROW	$69M	⬇ 16%

2020 Full-Year Guidance [3]

Net Sales	Adjusted Diluted EPS
-7% to -17%	$1.15 - $1.35

"Responding to current conditions, we implemented actions to continue serving our patients, their families and physicians. At the same time, we reduced expenses, improved liquidity and increased financial flexibility. I am proud of our employees' determination in overcoming the challenges created by COVID-19. While COVID-19 continues to impact our business, we are encouraged by several trends and achievements, including a gradual improvement in procedure volumes, the full commercial release of LifeSPARC™ in the U.S. and the launch of Perceval Plus® in Europe."

– Damien McDonald, CEO

Other Highlights

Full commercial launch of LifeSPARC™

LIFE SUPPORT SIMPLIFIED

Published data demonstrating adjunctive VNS Therapy improves outcomes in TRBD patients

- Improves response rate
- Improves suicidality ideation
- Accelerates antidepressant response

AS PUBLISHED IN THE *INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS*
TRBD: Treatment-Resistant Bipolar Depression

Perceval® Plus launched in Europe

SUTURELESS SURGICAL AORTIC HEART VALVE

1) Adjusted financial measures are non-GAAP measures and exclude specified items as described and reconciled in the "Reconciliation of GAAP to non-GAAP Financial Measures" contained on the back of this document. All EPS measures in this document refer to diluted EPS from continuing operations. 2) Unless otherwise noted, all sales growth rates in this document reflect constant-currency sales growth, which eliminates the effects of foreign currency fluctuations. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. 3) LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted diluted earnings per share guidance exclude other items such as, but not limited to, stock-based compensation costs, changes in fair value of contingent consideration arrangements and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net sales and adjusted diluted earnings per share are net sales and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs and the tax impact of the aforementioned items, tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES – UNAUDITED

Three Months Ended June 30, 2020

	GAAP Financial Measures	Merger and Integration Expenses (A)	Restructuring Expenses (B)	Depreciation and Amortization Expenses (C)	Product Remediation Expenses (D)	Non-recurring Legal and Contingent Consideration (E)	Stock-based Compensation Costs (F)	Certain Tax Adjustments (G)	Certain Interest Adjustments (H)	Financing Transactions (I)	Adjusted Financial Measures
Gross Margin	66.5%	--	--	0.2%	2.3%	(8.5)%	0.2%	--	--	--	60.7%
Operating Margin	(8.4)%	1.1%	0.4%	5.4%	2.3%	(10.1)%	5.5%	--	--	1.4%	(2.3)%
Diluted EPS – Continuing Operations	($1.81)	$0.04	$0.02	$0.17	$0.08	($0.39)	$0.21	$1.40	$0.07	$0.05	($0.15)

Three Months Ended June 30, 2019

	GAAP Financial Measures	Merger and Integration Expenses (A)	Restructuring Expenses (B)	Depreciation and Amortization Expenses (C)	Product Remediation Expenses (D)	Non-recurring Legal, Contingent Consideration and Other Reserves (E)	Stock-based Compensation Costs (F)	Certain Tax Adjustments (G)	Certain Interest Adjustments (H)	Impairments (J)	Acquisition Costs (K)	Adjusted Financial Measures
Gross Margin	71.1%	--	--	0.3%	1.8%	(4.2)%	0.3%	--	--	--	--	69.3%
Operating Margin	(10.8)%	1.6%	0.5%	3.7%	1.8%	(2.6)%	3.1%	--	--	18.5%	0.2%	15.9%
Diluted EPS – Continuing Operations	($0.61)	$0.07	$0.02	$0.15	$0.07	($0.20)	$0.14	$0.22	$0.03	$0.80	$0.01	$0.70

GAAP results include:

(A) Merger and integration expenses related to our legacy companies and recent acquisitions

(B) Restructuring expenses related to organizational changes

(C) Includes depreciation and amortization associated with purchase price accounting

(D) Costs related to the 3T Heater-Cooler remediation plan

(E) Three-month period ended June 30, 2020 includes 3T Heater-Cooler litigation provision, legal expenses primarily related to 3T Heater-Cooler defense, settlements and other matters and remeasurement of contingent consideration related to acquisitions. Three-month period ended June 30, 2019 includes contingent consideration related to acquisitions and legal expenses primarily related to 3T Heater-Cooler defense and other matters.

(F) Non-cash expenses associated with stock-based compensation costs

(G) Primarily relates to discrete tax items and the tax impact of intercompany transactions

(H) Three-month period ended June 30, 2020 primarily includes non-cash interest expense on our Senior Secured Term Loan and Cash Exchangeable Senior Notes, interest related to the 3T Heater-Cooler matter and intellectual property migration. Three-month period ended June 30, 2019 primarily relates to intellectual property migration and other non-recurring impacts to interest expense

(I) Costs associated with our June 2020 financing transactions, including the mark-to-market adjustment for the exchangeable option feature and capped call derivatives

(J) Impairment of ImThera intangible assets and other long-lived assets

(K) Costs related to acquisitions

* Numbers may not add up precisely due to rounding.

NET SALES: COMPARISON OF ACTUAL RESULTS TO CONSTANT CURRENCY – UNAUDITED[1]

(U.S. dollars in millions)

Business / Product Line	Three Months Ended June 30, 2020	Three Months Ended June 30, 2019	% Change at Actual Currency Rates	% Change at Constant-Currency Rates
Cardiovascular	124.5	172.2	(27.7%)	(26.2%)
Neuromodulation	57.2	104.3	(45.1%)	(44.7%)
Other	0.5	0.7	(30.0%)	(28.5%)
Total Net Sales	**182.2**	**277.2**	**(34.3%)**	**(33.1%)**

Region	Three Months Ended June 30, 2020	Three Months Ended June 30, 2019	% Change at Actual Currency Rates	% Change at Constant-Currency Rates
US	78.2	134.6	(41.9%)	(41.9%)
Europe	35.4	58.2	(39.2%)	(37.9%)
Rest of World	68.7	84.4	(18.7%)	(15.9%)
Total Net Sales	**182.2**	**277.2**	**(34.3%)**	**(33.1%)**

(1) Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period. The sales results presented are unaudited. Numbers may not add up or recalculate precisely due to rounding.